S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
Is This The End of Capitalism? (Ad)
Lots of sound and fury on US debt, but not a crisis — yet
Italy's premier visits Libya for talks on energy, migration
Is This The End of Capitalism? (Ad)
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
Online system to seek asylum in US is quickly overwhelmed
The Next Big Crisis Is Here (Ad)
Challenge for Tunisian democracy: Getting voters to show up
Is tipping getting out of control? Many consumers say yes
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
Is This The End of Capitalism? (Ad)
Lots of sound and fury on US debt, but not a crisis — yet
Italy's premier visits Libya for talks on energy, migration
Is This The End of Capitalism? (Ad)
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
Online system to seek asylum in US is quickly overwhelmed
The Next Big Crisis Is Here (Ad)
Challenge for Tunisian democracy: Getting voters to show up
Is tipping getting out of control? Many consumers say yes
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
Is This The End of Capitalism? (Ad)
Lots of sound and fury on US debt, but not a crisis — yet
Italy's premier visits Libya for talks on energy, migration
Is This The End of Capitalism? (Ad)
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
Online system to seek asylum in US is quickly overwhelmed
The Next Big Crisis Is Here (Ad)
Challenge for Tunisian democracy: Getting voters to show up
Is tipping getting out of control? Many consumers say yes
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
Is This The End of Capitalism? (Ad)
Lots of sound and fury on US debt, but not a crisis — yet
Italy's premier visits Libya for talks on energy, migration
Is This The End of Capitalism? (Ad)
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
Online system to seek asylum in US is quickly overwhelmed
The Next Big Crisis Is Here (Ad)
Challenge for Tunisian democracy: Getting voters to show up
Is tipping getting out of control? Many consumers say yes
NASDAQ:BLFS

BioLife Solutions - BLFS Stock Forecast, Price & News

$23.50
-0.30 (-1.26%)
(As of 01/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$23.37
$24.15
50-Day Range
$16.95
$25.18
52-Week Range
$10.40
$31.11
Volume
279,246 shs
Average Volume
291,090 shs
Market Capitalization
$1.01 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$31.20

BioLife Solutions MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
32.8% Upside
$31.20 Price Target
Short Interest
Healthy
5.92% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.70mentions of BioLife Solutions in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$2.47 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.63) to ($0.34) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.21 out of 5 stars

Medical Sector

422nd out of 1,054 stocks

Electromedical Equipment Industry

11th out of 24 stocks


BLFS stock logo

About BioLife Solutions (NASDAQ:BLFS) Stock

BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. It markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was incorporated in 1987 and is headquartered in Bothell, Washington.

Receive BLFS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioLife Solutions and its competitors with MarketBeat's FREE daily newsletter.

BLFS Stock News Headlines

Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
BioLife Solutions
Should You Invest in BioLife Solutions (BLFS)?
BioLife Solutions Expands Intellectual Property Estate
Earnings Outlook For BioLife Solutions
See More Headlines
Receive BLFS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioLife Solutions and its competitors with MarketBeat's FREE daily newsletter.

BLFS Company Calendar

Last Earnings
11/09/2022
Today
1/29/2023
Next Earnings (Estimated)
2/27/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Electromedical equipment
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BLFS
Employees
432
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$31.20
High Stock Price Forecast
$34.00
Low Stock Price Forecast
$29.00
Forecasted Upside/Downside
+32.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-7,640,000.00
Pretax Margin
-72.07%

Debt

Sales & Book Value

Annual Sales
$119.16 million
Book Value
$11.80 per share

Miscellaneous

Free Float
41,355,000
Market Cap
$1.01 billion
Optionable
Not Optionable
Beta
1.75

Key Executives

  • Mr. Michael P. RiceMr. Michael P. Rice (Age 60)
    Chairman & CEO
    Comp: $1.24M
  • Mr. Troy WichtermanMr. Troy Wichterman (Age 38)
    Chief Financial Officer
    Comp: $290.72k
  • Dr. Aby J. MathewDr. Aby J. Mathew (Age 51)
    Chairman of Scientific Advisory Board, Exec. VP & Chief Scientific Officer
    Comp: $638.79k
  • Mr. Marcus SchulzMr. Marcus Schulz (Age 44)
    Chief Revenue Officer
    Comp: $778.22k
  • Mr. Geraint Phillips
    Sr. VP of Global Operations
  • Mr. Todd BerardMr. Todd Berard (Age 54)
    Chief Marketing Officer
  • Ms. Sarah Aebersold J.D.Ms. Sarah Aebersold J.D. (Age 47)
    VP of Global HR
  • Ms. Karen FosterMs. Karen Foster (Age 63)
    Chief Quality Officer













BLFS Stock - Frequently Asked Questions

Should I buy or sell BioLife Solutions stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BioLife Solutions in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BLFS shares.
View BLFS analyst ratings
or view top-rated stocks.

What is BioLife Solutions' stock price forecast for 2023?

1 equities research analysts have issued 1 year price objectives for BioLife Solutions' stock. Their BLFS share price forecasts range from $29.00 to $34.00. On average, they predict the company's share price to reach $31.20 in the next twelve months. This suggests a possible upside of 32.8% from the stock's current price.
View analysts price targets for BLFS
or view top-rated stocks among Wall Street analysts.

How have BLFS shares performed in 2023?

BioLife Solutions' stock was trading at $18.20 at the beginning of 2023. Since then, BLFS shares have increased by 29.1% and is now trading at $23.50.
View the best growth stocks for 2023 here
.

Are investors shorting BioLife Solutions?

BioLife Solutions saw a drop in short interest in the month of January. As of January 15th, there was short interest totaling 2,330,000 shares, a drop of 5.7% from the December 31st total of 2,470,000 shares. Based on an average daily volume of 379,600 shares, the short-interest ratio is presently 6.1 days. Currently, 5.9% of the shares of the stock are short sold.
View BioLife Solutions' Short Interest
.

When is BioLife Solutions' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023.
View our BLFS earnings forecast
.

How were BioLife Solutions' earnings last quarter?

BioLife Solutions, Inc. (NASDAQ:BLFS) released its quarterly earnings results on Wednesday, November, 9th. The medical equipment provider reported ($0.15) EPS for the quarter, missing analysts' consensus estimates of ($0.12) by $0.03. The medical equipment provider earned $40.75 million during the quarter, compared to analysts' expectations of $41.63 million. BioLife Solutions had a negative net margin of 67.70% and a negative trailing twelve-month return on equity of 7.50%.

What guidance has BioLife Solutions issued on next quarter's earnings?

BioLife Solutions issued an update on its FY 2022 earnings guidance on Saturday, January, 28th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $161.90 million-$161.90 million, compared to the consensus revenue estimate of $160.92 million.

What is Mike Rice's approval rating as BioLife Solutions' CEO?

14 employees have rated BioLife Solutions Chief Executive Officer Mike Rice on Glassdoor.com. Mike Rice has an approval rating of 100% among the company's employees. This puts Mike Rice in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 89.0% of employees surveyed would recommend working at BioLife Solutions to a friend.

What other stocks do shareholders of BioLife Solutions own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioLife Solutions investors own include Micron Technology (MU), AbbVie (ABBV), Cara Therapeutics (CARA), Gilead Sciences (GILD), Pfizer (PFE), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), Twilio (TWLO) and Verastem (VSTM).

What is BioLife Solutions' stock symbol?

BioLife Solutions trades on the NASDAQ under the ticker symbol "BLFS."

Who are BioLife Solutions' major shareholders?

BioLife Solutions' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Stephens Investment Management Group LLC (0.92%), Peregrine Capital Management LLC (0.67%), Stephens Inc. AR (0.34%), Yousif Capital Management LLC (0.05%), Comerica Bank (0.05%) and Greenwood Capital Associates LLC (0.05%). Insiders that own company stock include Aby J Mathew, Aby J Mathew, Amy Duross, Andrew G Hinson, Andrew G Hinson, Casdin Partners Master Fund, L, Greef Roderick De, James Mathers, Joseph C Schick, Karen A Foster, Karen A Foster, Marcus Schulz, Michael Rice, Of The University Of C Regents, Raymond W Cohen, Sarah Aebersold, Thomas Girschweiler, Todd Berard, Troy Wichterman and Walter Villiger.
View institutional ownership trends
.

How do I buy shares of BioLife Solutions?

Shares of BLFS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BioLife Solutions' stock price today?

One share of BLFS stock can currently be purchased for approximately $23.50.

How much money does BioLife Solutions make?

BioLife Solutions (NASDAQ:BLFS) has a market capitalization of $1.01 billion and generates $119.16 million in revenue each year. The medical equipment provider earns $-7,640,000.00 in net income (profit) each year or ($2.48) on an earnings per share basis.

How many employees does BioLife Solutions have?

The company employs 432 workers across the globe.

How can I contact BioLife Solutions?

BioLife Solutions' mailing address is 3303 MONTE VILLA PARKWAY SUITE 310, BOTHELL WA, 98021. The official website for the company is www.biolifesolutions.com. The medical equipment provider can be reached via phone at (425) 402-1400, via email at rdegreef@biolifesolutions.com, or via fax at 425-402-1433.

This page (NASDAQ:BLFS) was last updated on 1/29/2023 by MarketBeat.com Staff